<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01385319</url>
  </required_header>
  <id_info>
    <org_study_id>ZEUS-10-II</org_study_id>
    <nct_id>NCT01385319</nct_id>
  </id_info>
  <brief_title>Zotarolimus-eluting Endeavor Sprint Stent in Uncertain DES Candidates (ZEUS) Study</brief_title>
  <acronym>ZEUS</acronym>
  <official_title>Zotarolimus-eluting Endeavor Sprint Stent in Uncertain DES Candidates (ZEUS) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marco Valgimigli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universit√† degli Studi di Ferrara</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To prospectively evaluate in a multicenter open label trial whether the use of&#xD;
      zotarolimus-eluting ENDEAVOR Stent implantation in patients at low restenosis or at high&#xD;
      bleeding or thrombotic risk will decrease the incidence of 12-month major adverse cardiac&#xD;
      events (MACE) including overall death, any myocardial infarction (MI) or any target vessel&#xD;
      revascularization (TVR).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to conduct a multicenter, international, randomized trial to test&#xD;
      whether the Endeavor stent is superior to BMS in terms of efficacy and safety in&#xD;
&#xD;
        1. Patients with coronary artery disease lesions at low risk of in-stent restenosis;&#xD;
&#xD;
        2. Patients at high risk for bleeding or carrying impossibility to comply with dual&#xD;
           anti-platelet treatment at long-term.&#xD;
&#xD;
        3. Patients at high thrombosis risk due to systemic disorders or planned non-cardiac&#xD;
           surgery within 12 months&#xD;
&#xD;
      As the use of DES in these two patient/lesion subsets is debated due to lack of evidence,&#xD;
      patients fulfilling at least one of these three medical conditions qualify for bare metal&#xD;
      stent implantation and physicians may believe DES to be even contra-indicated in such cases.&#xD;
      The current protocol has been developed on purpose to address the value of the Endeavor&#xD;
      Sprint stent, which differs in many aspects from other FDA approved DES, including fast and&#xD;
      complete degree of strut coverage after implantation and quick release of active drug after&#xD;
      deployment (~15 days) which may help decreasing the need for prolonged dual antiplatelet&#xD;
      treatment down to 1 month as it is currently recommended for bare metal stent implantation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MACE</measure>
    <time_frame>12 months</time_frame>
    <description>Major adverse cardiovascular events including death for any cause, non-fatal myocardial infarction or target vessel revascularisation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>myocardial infarction</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TVR</measure>
    <time_frame>12 months</time_frame>
    <description>target vessel revascularisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stent thrombosis</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1606</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>bare metal stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Endeavor sprint stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bare metal stent implantation</intervention_name>
    <description>After BMS implantation the duration of dual anti-platelet therapy is a function of the clinical presentation and the bleeding risk a given patient as follows:&#xD;
Clopidogrel will be given for 1 month after PCI if indication to the procedure is stable coronary artery disease or for at least 6 month if indication to the procedure is ACS, including STEMI or NSTEACS. At discretion of the treating physician, prasugrel or ticagrelor may replace clopidogrel in ACS patients.&#xD;
Patients recruited in the study due to high bleeding risk will receive clopidogrel for at least 30 days.&#xD;
Patients recruited in the study due to high thrombosis risk will receive clopidogrel monotherapy life long or DAPT for at least 1 month.</description>
    <arm_group_label>bare metal stent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>zotarolimus eluting stent</intervention_name>
    <description>After ZES implantation the duration of dual anti-platelet therapy is a function of the clinical presentation and the bleeding risk a given patient (i.e. identical to criteria set out for BMS patients) as follows:&#xD;
Clopidogrel will be given for 1 month after PCI if indication to the procedure is stable coronary artery disease or for at least 6 month if indication to the procedure is ACS, including STEMI or NSTEACS. At discretion of the treating physician, prasugrel or ticagrelor may replace clopidogrel in ACS patients.&#xD;
Patients recruited in the study due to high bleeding risk will receive clopidogrel for at least 30 days.&#xD;
Patients recruited in the study due to high thrombosis risk will receive clopidogrel monotherapy life long or DAPT for at least 1 month.</description>
    <arm_group_label>Endeavor sprint stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        A) low restenosis risk based on angiographic findings defined as follows:&#xD;
&#xD;
        ----patients will be considered at low restenosis risk if no planned stent lower than 3.0&#xD;
        mm is intended to be implanted in lesions expect left main or vein graft&#xD;
&#xD;
        B) high bleeding risk and/or presence of relative-absolute contraindication to dual&#xD;
        anti-platelet treatment beyond 30 days defined as follows:&#xD;
&#xD;
          1. Clinical indication to treatment with oral anticoagulant, including use of warfarin or&#xD;
             dabigatran or other oral anticoagulant agents&#xD;
&#xD;
          2. Recent (within previous 12 months) bleeding episode(s) which required medical&#xD;
             attention&#xD;
&#xD;
          3. Previous bleeding episode(s) which required hospitalization if the bleeding diathesis&#xD;
             has not been completely resolved (i.e. surgical removal of the bleeding source)&#xD;
&#xD;
          4. Age greater than 80&#xD;
&#xD;
          5. Systemic conditions associated to increased bleeding risk (e.g. hematological&#xD;
             disorders or any known coagulopathy determining bleeding diathesis, including history&#xD;
             of or current thrombocytopenia defined as platelet count &lt;100,000/mm3 (&lt;100 x 109/L).&#xD;
&#xD;
          6. Known Anemia defined as repeatedly documented hemoglobin lower than 10 gr/dl which is&#xD;
             not due to an acute and documented blood loss&#xD;
&#xD;
          7. Need for chronic treatment with steroids or NSAID&#xD;
&#xD;
        C) Patients at high thrombosis risk based on the presence of at least one of the following&#xD;
        criteria:&#xD;
&#xD;
          1. Allergy/intolerance to aspirin&#xD;
&#xD;
          2. Allergy/intolerance to clopidogrel AND ticlopidine&#xD;
&#xD;
          3. Planned surgery (other than skin) within 12 months of percutaneous coronary&#xD;
             intervention (PCI).&#xD;
&#xD;
          4. patient with cancers (other than skin) and life expectancy &gt;1 year&#xD;
&#xD;
          5. Patients with systemic conditions associated with thrombosis diathesis (e.g.,&#xD;
             hematologic disorders and any known systemic conditions determining a pro-thrombotic&#xD;
             state including immunological disorders)&#xD;
&#xD;
             -&#xD;
&#xD;
             Exclusion Criteria:&#xD;
&#xD;
               -  Any of the following:&#xD;
&#xD;
                    1. Women who are pregnant. Women of childbearing potential must have a negative&#xD;
                       pregnancy test (urine or serum HCG) within 7 days prior to randomization; as&#xD;
                       close to randomization as possible, within 24 hours preferred.&#xD;
&#xD;
                    2. Subjects who are unable to give informed consent and assurance for complete&#xD;
                       contact through 12 months.&#xD;
&#xD;
                    3. PCI with stenting in the previous 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Albert Szent-Gy√∂rgyi Clinical Center, University of Szeged</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Donato</name>
      <address>
        <city>Arezzo</city>
        <state>AR</state>
        <zip>52100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti di Bergamo</name>
      <address>
        <city>Bergamo</city>
        <state>BG</state>
        <zip>24128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico San Marco</name>
      <address>
        <city>Zingonia</city>
        <state>BG</state>
        <zip>24040</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Savigliano</name>
      <address>
        <city>Savigliano</city>
        <state>CN</state>
        <zip>12038</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Sant'Ambrogio</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20149</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Unita' Sanitaria Locale Di Modena - Ospedale Baggiovara</name>
      <address>
        <city>Modena</city>
        <state>MO</state>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Parma</name>
      <address>
        <city>Parma</city>
        <state>PR</state>
        <zip>43126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <state>PV</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Ravenna</name>
      <address>
        <city>Ravenna</city>
        <state>RA</state>
        <zip>48121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Ordine Mauriziano di Torino, Ospedale Umberto I</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Giovanni Bosco</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10154</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Ferrara</name>
      <address>
        <city>Ferrara</city>
        <zip>44100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Mediterranea</name>
      <address>
        <city>Naples</city>
        <zip>80122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Santa Cruz</name>
      <address>
        <city>Carnaxide</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Geneva</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Portugal</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>June 24, 2011</study_first_submitted>
  <study_first_submitted_qc>June 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2011</study_first_posted>
  <last_update_submitted>October 6, 2012</last_update_submitted>
  <last_update_submitted_qc>October 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Universit√† degli Studi di Ferrara</investigator_affiliation>
    <investigator_full_name>Marco Valgimigli</investigator_full_name>
    <investigator_title>Head of the Catheterization laboratory</investigator_title>
  </responsible_party>
  <keyword>Bare metal stent</keyword>
  <keyword>zotarolimus eluting stent</keyword>
  <keyword>triple anti-thrombotic therapy</keyword>
  <keyword>high bleeding riskduration of dual anti-platelet therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

